Icariin, a compound derived from the precious Chinese medicinal herb Epimedium, shows significant therapeutic potential against liver cancer. However, extracting icariin is notoriously difficult. Currently, most market manufacturers rely on chemical extraction or direct synthesis, which yield poor results and cause heavy pollution. While traditional enzymatic methods exist, they use standard commercial enzymes that only convert a single component, resulting in very low conversion rates.
To break this bottleneck, our company partnered with the “Enzyme Future” team from the College of Chemical Engineering to develop a game-changing solution. Targeting the specific traits of Epimedium total flavonoids, we utilized modern biotechnologies—such as genetic modification and cloning expression—to create a unique, highly efficient biological enzyme.
This innovation delivers three core breakthroughs:
- 5-in-1 Directional Conversion: This specialized enzyme directionally converts all 5 flagship flavonoids within Epimedium into icariin.
- 95% Conversion & 98% Purity: Our process drives the icariin conversion rate up to 95% and pushes product purity past 98%, drastically maximizing both yield and quality.
- Innovative Immobilization Cuts Costs by 70%: By integrating advanced enzyme immobilization technology, the enzyme retains 90% of its initial activity even after 20 repeated uses. This reuse cuts overall enzyme costs by 70%.
Furthermore, our biological approach drastically limits chemical reagent usage, paving the way for eco-friendly, low-pollution manufacturing.
Today, our team has officially moved this premium icariin product into full-scale production. This milestone will accelerate global anti-cancer drug development and ultimately bring life-saving benefits to cancer patients worldwide.
Spanish 
English